Skip to main content Skip to section navigation Skip to footer
French

Acasti Pharma Inc.

  • English
  • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Clinical Pipeline
    • GTX-104
    • GTX-102
    • GTX-101
  • Investor Relations
    • Overview
    • News / Events
    • Company Info
    • Financial Results
    • Stock Data
    • Regulatory Filings
    • Governance
  • Newsroom
  • Careers
  • Contact
  • French

Press Releases

Investor Relations

Investor Relations

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Media
    • IR Calendar
    • Email Alerts
    • Grace Merger Conference Call
  • Company Info
    • Overview
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • NASDAQ: ACST
    • TSXV: ACST
    • Analyst Coverage
  • Regulatory Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • SEDAR
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News / Events

  • Overview
  • Press Releases
  • Media
  • IR Calendar
  • Email Alerts
  • Grace Merger Conference Call

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Dec 22, 2022

Acasti Pharma Reports Second Quarter 2023 Operational Results

Nov 14, 2022

Acasti Pharma to Present at Q4 Investor Summit

Nov 9, 2022

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

Nov 7, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

Sep 30, 2022

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Sep 29, 2022

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Sep 14, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Sep 13, 2022

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 12, 2022

Acasti Pharma Reports First Quarter 2023 Operational Results

Aug 11, 2022
rss_feed News RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...25
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Acasti Pharma Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap